Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
05
05
2021
received:
29
03
2021
accepted:
27
05
2021
entrez:
2
12
2021
pubmed:
3
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
It is well known that organ transplant recipients are prone to develop non-melanoma skin cancers, particularly cutaneous squamous cell carcinoma (cSCC). This is explained by the long-term use of immunosuppressants and thus the decrease of the immunosurveillance that protects from developing malignant tumours. Solid organ transplant recipients (SOTRs) are 65-250 times more likely to develop cSCC compared to the general population (Am J Transplant 2017; 17: 2509). Moreover, in these patients cSCCs follow a more aggressive course. Close follow-up and regular skin check-ups by a dermatologist are, therefore, crucial in the management of these patients. When detected early, cSCC can be easily and effectively treated by a simple excision. However, when advanced, outcomes are poor. Immune checkpoints inhibitors (ICIs) have been recently added to our arsenal and represent a breakthrough, having proved to be effective in achieving long-term responses. We, hereby, present two cases of difficult-to-treat cSCCs in renal transplanted patients.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
cemiplimab
6QVL057INT
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-58Informations de copyright
© 2021 European Academy of Dermatology and Venereology.
Références
Stratigos AJ, Garbe C, Dessinioti C et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer 2020; 128: 83-102.
Harris BN, Bayoumi A, Rao S, Moore MG, Farwell DG, Bewley AF. Factors associated with recurrence and regional adenopathy for head and neck cutaneous squamous cell carcinoma. Otolaryngol Head Neck Surg 2017; 156: 863-869.
Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol 2013; 149: 541-547.
Manyam BV, Garsa AA, Chin RI et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer 2017; 123: 2054-2060.
De Bruyn P, Van Gestel D, Ost P et al. Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go? Curr Opin Oncol 2019; 31: 54-64.
Migden MR, Rischin D, Schmults CD et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 2018; 379: 341-351.
Palma DA, Olson R, Harrow S et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET Phase II randomized trial. J Clin Oncol 2020; 38: 2830-2838.
Tsung I, Worden FP, Fontana RJ. A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma. Oncologist 2021; 26: 133-138
Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. J Am Acad Dermatol 2020; 82: 1490-1500.
d’Izarny-Gargas T, Durrbach A, Zaidan M. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review. Am J Transplant 2020; 20(9): 2457-2465.
Lai HC, Lin JF, Hwang TIS, Liu YF, Yang AH, Wu CK. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? Int J Mol Sci 2019; 20: 1-12.
Abdel-Wahab N, Safa H, Abudayyeh A et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature. J Immunother Cancer 2019; 7: 1-10.
Kumar V, Shinagare AB, Rennke HG et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 2020; 25: 505-514.
Franzin R, Netti GS, Spadaccino F et al. The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand? Front Immunol 2020; 11: 1-20.
Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. Kidney Int 2017; 91: 954-963.
Dantal J, Morelon E, Rostaing L et al. Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results. J Clin Oncol 2018; 36: 2612-2620.
El Hage A, Dormond O. Combining mtor inhibitors and t cell-based immunotherapies in cancer treatment. Cancers (Basel) 2021; 13: 1-19.